Phase 2 N=23 Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Childhood Germ Cell Tumor · Ovarian Cancer · Teratoma
Primary: Overall Survival (OS) — 86; 56 percentage of participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=183 Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project
Giant Cell Tumors
Primary: Number of Participants According to the Management Plan in Patients With Diffuse TGCT (d-TGCT) — 94; NA; NA; NA Participants
N/A N=668 Genetic Risk Assessment for Cancer Education and Empowerment (GRACE) Project
Breast Cancer · Ovarian Cancer
Primary: Medically Verified Cancer Genetic Risk Assessment Uptake at 6 Months — 5; 6; 32 Participants — p=<.0001
Phase 2 N=10 Gemcitabine, Paclitaxel and Oxaliplatin (GemPOx)
CNS Germ Cell Tumor
Primary: Response Rate — 0; 0; 4; 2 Participants
N/A N=80 The Second-Generation MCCG for Upper Gastrointestinal Tract.
Capsule Endoscopy
Primary: Circumferential Visualization of the Z-line — 0; 5; 5; 7 Participants
Phase 3 N=32 A Phase III Trial to Assess the Safety and Efficacy of Plant Cell Expressed GCD in Patients With Gaucher Disease
Gaucher Disease
Primary: Change From Baseline in Spleen Volume Measured by MRI. — -26.91; -38.01 percentage of change — p=<0.0001
Phase 3 N=240 Methotrexate Compared With Dactinomycin in Treating Patients With Gestational Trophoblastic Neoplasia
Good Prognosis Metastatic Gestational Trophoblastic Tumor · Hydatidiform Mole · Non-Metastatic Gestational Trophoblastic Tumor
Primary: Response Based on Blood Human Chorionic Gonadotropin (hCG) Assay — 57; 76; 48; 29 Participants
N/A N=62 Immunohistochemical Evaluation of Protein P16 Expression in Ovarian Germ Cell Tumors.
Ovarian Neoplasms · Germ Cell Tumors · Immunohistochemistry
Primary: P16 Evaluation in Ovarian Germ Cell Tumors — 7; 4; 0; 6 units on a scale — p=0.001
Phase 2 N=89 ATG-GCSF in New Onset Type 1 Diabetes
Diabetes Mellitus, Type 1
Primary: Change in Area Under the Stimulated C-peptide Curve From Baseline to 12 Months. — 0.528; 0.646; 0.406 nmol/L
N/A N=43 The Glucagon Stimulation Test for Evaluation of Adult Growth Hormone Deficiency and Adrenocorticotropic Axis
Adult Growth Hormone Deficiency · Hypothalamic-pituitary Disorders
Primary: Peak GH Level in Adult Patients With Hypothalamic-pituitary Disorders and 1-2 Pituitary Hormone Deficiency (PHD). — 0.9; 0.6; 0.7 ng/mL
N/A N=285 Get Connected Efficacy Trial
HIV Infections
Primary: Percent of Participants Reporting Changes in Their HIV Testing Behavior Using Self-report Questionnaires — 53; 54 Participants
Phase 2 N=279 Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)
Acute Leukemia · Chronic Myelogenous Leukemia · Myelodysplasia
Primary: Percentage of Participants With GVHD/Relapse or Progression-free Survival (GRFS) — 35.5; 27.2; 44.1 percentage of participants
Phase 3 N=44 Plant Cell Expressed Recombinant Human Glucocerebrosidase Extension Trial
Gaucher Disease
Primary: Spleen Volume — 2324.0; 2120.0; 778.0; 1707.7 mL
Phase 2 N=180 Treatment for Acute Graft-Versus-Host Disease (BMT CTN 0302)
Graft vs Host Disease · Immune System Disorders
Primary: Number of Complete Response (CR) at Day 28 of Therapy — 12; 27; 25; 16 participants
Phase 2 N=60 Combination Chemotherapy and Pegfilgrastim in Treating Patients With Previously Untreated Germ Cell Tumors
Brain and Central Nervous System Tumors · Extragonadal Germ Cell Tumor · Ovarian Cancer
Primary: Rate of Complete Response — 38; 7; 11 Participants
N/A N=42 Geriatric Core Dataset (G-CODE) for Clinical Research in Elderly Cancer Patients
Cancer
Primary: Number of Experts Who Considered That the Question "Do You Live Alone ?" Should be Retained in the G-CODE — 42 Participants
N/A N=358 Trifecta™ GT Post Market Clinical Follow-up
Aortic Valve Disease · Aortic Valve Disorder
Primary: Freedom From Surgical Valve Replacement or Transcatheter Valve-in-Valve Implantation — 95.8 percentage of participants
Phase 2 N=379 A Study of Tacrolimus/Methotrexate and Tocilizumab to Prevent Acute Graft-Versus-Host Disease (AGVD) After Allogeneic Hematopoietic Stem Cell Transplant
Hematopoietic Stem Cell Transplantation
Primary: Number of Subjects Not Experiencing Grade II-IV Acute Graph Versus Host Disease (aGVHD) — 3; 18; 0 Participants
Phase 2 N=29 PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
Hematologic Malignancy
Primary: The Number of Patients With GVHD/Relapse-free (GRFS) Survival — 25 Participants
Phase 2 N=532 Study of Denosumab in Subjects With Giant Cell Tumor of Bone
Cancer · Giant Cell Tumors · Giant Cell Tumor of Bone
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 260; 231; 12; 98 Participants
N/A N=127 Observational Registry Characterizing the CTAG Device With ACTIVE CONTROL
Thoracic Diseases
Primary: Number of Subjects With Procedural Technical Success — 123 Participants
Phase 3 N=57 Dactinomycin or Methotrexate in Treating Patients With Low-Risk Gestational Trophoblastic Neoplasia
Choriocarcinoma · FIGO Stage I Gestational Trophoblastic Tumor · FIGO Stage II Gestational Trophoblastic Tumor
Primary: Percentage of Participants With Complete Response — 78.6; 88.5 percentage of participants
Phase 3 N=34 Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) ERT Compared With Imiglucerase in Type I Gaucher Disease
Gaucher Disease, Type 1
Primary: Mean Change From Baseline to Month 9 in Hemoglobin (Hgb) Concentration for Each Treatment Group. — 1.624; 1.488 gram per deciliter (g/dl)
N/A N=8 T-GENVIH-003 LTFU (Long Term Follow Up) Study
Hernia · Hernia, Ventral · Pathological Conditions, Anatomical
Primary: Number of Participants With Clinically Confirmed Recurrence — 2 Participants
Phase 2 N=64 High-dose Chemotherapy for Poor-Prognosis Relapsed Germ-Cell Tumors
Testicular Cancer
Primary: Number of Participants With 2-year Event-Free Survival (EFS) — 28; 11 Participants
Phase 3 N=302 Surgery and Combination Chemotherapy in Treating Children With Extracranial Germ Cell Tumors
Childhood Embryonal Tumor · Childhood Extracranial Germ Cell Tumor · Childhood Extragonadal Germ Cell Tumor
Primary: Event-Free Survival (EFS) — 87.0 Percent probability
Phase 2 N=108 Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Germ Cell Tumors
Extragonadal Germ Cell Tumor · Ovarian Cancer · Testicular Germ Cell Tumor
Primary: Overall Objective Response — 50; 4; 36; 8 participants
Phase 2 N=30 Tocilizumab for Patients With Giant Cell Arteritis
Giant Cell Arteritis
Primary: Number of Patients That Have Achieved Complete Remission of Disease — 17; 4 Participants — p=0.0301
Phase 2 N=91 Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)
Gastrointestinal Stromal Tumor (GIST)
Primary: Recurrence-free Survival up to 60 Months — 9; 7; 2; 82 participants with an event
Phase 1 N=24 A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab (TCZ) Administered to Participants With Giant Cell Arteritis (GCA).
Giant Cell Arteritis
Primary: Maximum Serum Concentration (Cmax) of TCZ — 197; 178 ug/mL